Download PDF
Horm Metab Res 2019; 51(04): 230-242
DOI: 10.1055/a-0863-5779
Review
© Georg Thieme Verlag KG Stuttgart · New York

Serum Prostate-Specific Antigen Level in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

Arezoo Maleki-Hajiagha
1   Research Development Center, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran
,
Maryam Razavi
2   Pregnancy Health Research Center, Department of Obstetrics and Gynecology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
,
Mahroo Rezaeinejad
3   Department of Obstetrics and Gynecology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
,
Mahdi Sepidarkish
4   Department of Biostatistics and Epidemiology, Babol University of Medical Sciences, Babol, Iran
,
Ahmad Mehri
5   Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Science, Tehran, Iran
,
Samira Vesali
6   Department of Epidemiology and Reproductive Health, Reproductive Epidemiology Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
,
Zahra Allameh
7   Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
› Author Affiliations
Further Information

Publication History

received 26 March 2018

Publication Date:
25 April 2019 (online)

Also available at
    Permissions and Reprints

Abstract

We undertook a comprehensive search of all published original articles evaluating the diagnostic value of prostate-specific antigen (PSA) for the detection of polycystic ovary syndrome (PCOS). Finally, 25 studies with a total of 1865 participants (1104 cases and 761 controls) met the inclusion criteria. Mean serum PSA levels were significantly higher in PCOS women compared to healthy women [Standardized mean difference (SMD)=1.73 ng/ml, 95% CI=1.22 to 2.25, p<0.001]. Only 5 studies reported accuracy indicators and were included in the bivariate random-effects model; with a total of 509 samples that included 332 (65.22%) confirmed PCOS women. The sensitivity of serum PSA for the diagnosis of PCOS varied between 66.3 and 90.6%, and, the specificity ranged from 62.5–86.7%. Meta-analysis revealed a pooled sensitivity of 72.3% (95% CI 67.1–77.00%) and specificity of 74.6% (95% CI 67.5–80.8%) with an area under the summary ROC curve equal to 0.82 (95% CI 0.75–0.83). The summary estimates were 2.92 (95% CI 1.98–4.31) for positive LR and 0.37 (95% CI 0.26–0.51) for negative LR. The pooled estimate of diagnostic odds ratio (DOR) of serum PSA was 9.01 (95% CI 4.35–18.64). Considering the methodological weaknesses existed in studies, lack of sufficient data regarding the accuracy indicators, and the complexity of the exact pathophysiology of PSA secretion in women, the precise position of PSA, as a diagnostic test for the detection of PCOS, in clinical practice is undetermined, and further studies are still needed.

Key words

prostate-specific antigen - insulin resistance - polycystic ovary syndrome

Supplementary Material

Letter to this article:

Concerning the Article by Arezoo Maleki-Hajiagha et al. entitled: Serum Prostate-Specific Antigen Level in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysisHorm Metab Res 2020; 52(04): 251-251
DOI: 10.1055/a-1089-7739

Letter to this article:

Response to Letter to the Editor Entitled: Concerning the Article by Arezoo Maleki-Hajiagha et al. Entitled Serum Prostate-Specific Antigen Level in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-AnalysisHorm Metab Res 2020; 52(04): 252-252
DOI: 10.1055/a-1089-7970

 

  • References

  • 1 Azziz R, Carmina E, Dewailly D. et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril 2009; 91: 456-488
    CrossrefPubMedGoogle Scholar
  • 2 Di Fede G, Mansueto P, Pepe I. et al. High prevalence of polycystic ovary syndrome in women with mild hirsutism and no other significant clinical symptoms. Fertil Steril 2010; 94: 194-197
    CrossrefPubMedGoogle Scholar
  • 3 Norman RJ, Dewailly D, Legro RS. et al. Polycystic ovary syndrome. Lancet 2007; 370: 685-697
    CrossrefPubMedGoogle Scholar
  • 4 Martin KA, Chang RJ, Ehrmann DA. et al. Evaluation and treatment of hirsutism in premenopausal women: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 1105-1120
    CrossrefPubMedGoogle Scholar
  • 5 Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005; 353: 2578-2588
    CrossrefPubMedGoogle Scholar
  • 6 Souter I, Sanchez LA, Perez M. et al. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstetr Gynecol 2004; 191: 1914-1920
    CrossrefPubMedGoogle Scholar
  • 7 Mangelsdorf S, Otberg N, Maibach HI. et al Ethnic variation in vellus hair follicle size and distribution. Skin Pharmacol Physiol 2006; 19: 159-167
    CrossrefPubMedGoogle Scholar
  • 8 Amiri M, Ramezani Tehrani F, Nahidi F. et al. Association between biochemical hyperandrogenism parameters and Ferriman–Gallwey score in patients with polycystic ovary syndrome: a systematic review and meta-regression analysis. Clin Endocrinol 2017; 87: 217-230
    CrossrefPubMedGoogle Scholar
  • 9 Asunción M, Calvo RM, San Millàn JL. et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-2438
    PubMedGoogle Scholar
  • 10 Witchel SF, Oberfield S, Rosenfield RL. et al. The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr 2015; 83: 376-389
    CrossrefPubMedGoogle Scholar
  • 11 Goodman NF, Cobin RH, Futterweit W. et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1. Endocr Pract 2015; 21: 1291-1300
    CrossrefPubMedGoogle Scholar
  • 12 Rosner W, Vesper H. Toward excellence in testosterone testing: a consensus statement. J Cli Endocrinol Metab 2010; 95: 4542-4548
    PubMedGoogle Scholar
  • 13 Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8: 268-278
    CrossrefPubMedGoogle Scholar
  • 14 Wang M, Valenzuela L, Murphy G. et al. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-163
    PubMedGoogle Scholar
  • 15 Diamandis E, Yu H. New biological functions of prostate-specific antigen?. J Clin Endocrinol Metab 1995; 80: 1515-1517
    CrossrefPubMedGoogle Scholar
  • 16 Yu H, Diamandis EP, Sutherland DJ. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994; 27: 75-79
    CrossrefPubMedGoogle Scholar
  • 17 Burelli A, Cionini R, Rinaldi E. et al. Serum PSA levels are not affected by the menstrual cycle or the menopause, but are increased in subjects with polycystic ovary syndrome. J Endocrinol Invest 2006; 29: 308-312
    CrossrefPubMedGoogle Scholar
  • 18 Diamandis EP, Stanczyk FZ, Wheeler S. et al. Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). Clin Chem Lab Med 2017; 55: 1789-1797
    PubMedGoogle Scholar
  • 19 Obiezu CV, Scorilas A, Magklara A. et al. Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86: 1558-1561
    CrossrefPubMedGoogle Scholar
  • 20 Bahceci M, Bilge M, Tuzcu A. et al. Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+ desogestrel/ethinyl estradiol combination. J Endocrinol Invest 2004; 27: 353-356
    CrossrefPubMedGoogle Scholar
  • 21 Cebeci F, Onsun N, Ummetoglu O. et al. Serum prostatic specific antigen levels in women with hirsutism/Hirsutizmli kadinlarda serum prostatik spesifik antijen duzeyleri. Arch Turk Dermatol Venerol 2009; DOI: 104-107.
    CrossrefPubMedGoogle Scholar
  • 22 Güllü S, Emral R, Asik M. et al. Diagnostic value of prostatic specific antigen in hirsute women. J Endocrinol Inves 2003; 26: 1198-1202
    PubMedGoogle Scholar
  • 23 Guzelmeric K, Seker N, Unal O. et al. High serum prostate-specific antigen concentrations in hirsute women do not decrease with treatment by the combination of spironolactone and the contraceptive pill. Gynecol Endocrinol 2004; 19: 190-195
    CrossrefPubMedGoogle Scholar
  • 24 Kocak M. Serum levels of prostate-specific antigen and androgens after nasal administration of a gonadotropin releasing hormone-agonist in hirsute women. Gynecol Endocrinol 2004; 18: 179-185
    CrossrefPubMedGoogle Scholar
  • 25 Tokmak A, Bodur S, Erkilinc S. et al. The value of prostate-specific antigen in diagnosis of polycystic ovarian syndrome in adolescent girls. J Pediatr Adolesc Gynecol 2018; 31: 263-269
    CrossrefPubMedGoogle Scholar
  • 26 Vural B, Özkan S, Bodur H. Is prostate-specific antigen a potential new marker of androgen excess in polycystic ovary syndrome?. J Obstetr Gynaecol Res 2007; 33: 166-173
    PubMedGoogle Scholar
  • 27 Escobar-Morreale HcF, Àvila S, Sancho J. Serum prostate-specific antigen concentrations are not useful for monitoring the treatment of hirsutism with oral contraceptive pills. J Clin Endocrinol Metab 2000; 85: 2488-2492
    PubMedGoogle Scholar
  • 28 Escobar-Morreale HcF, Serrano-Gotarredona Jn, Avila S. et al. The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab 1998; 83: 2580-2584
    CrossrefPubMedGoogle Scholar
  • 29 Riesco O, Blaustein C, Scaglia J. et al. Niveles circulantes de Antígeno Específico de Próstata (PSA) en mujeres con hirsutismo idiopático (HI). RAEM 2005; 42: 109
    PubMedGoogle Scholar
  • 30 Negri C, Tosi F, Dorizzi R. et al. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: Evidence that serum PSA is a marker of androgen action in women. J Clin EndocrinolMetab 2000; 85: 81-84
    PubMedGoogle Scholar
  • 31 Camacho F, López-Elorza F, Rodríguez-Rey E. et al. Prostate-specific antigen levels as hyperandrogenism marker in women. J Eur Acad Dermatol Venereol 2009; 23: 221-223
    CrossrefPubMedGoogle Scholar
  • 32 Panigrahy R, Singh B, Pattnaik TK. et al. Role of insulin sensitising agents in altering PSA level in PCOS. Int J Reprod Contracep. Obstet Gynecol 2017; 6: 4986-4989
    PubMedGoogle Scholar
  • 33 Sharaf AE, El Mongy NN, Fawzy MM. et al. Prostate-specific antigen as a diagnostic marker in female hyperandrogenism. J Egypt Women Dermatol Soc 2013; 10: 58-62
    PubMedGoogle Scholar
  • 34 Metawie MAH, El Sarafy T, El-Kattan S. et al. Serum-prostatic specific antigen level as a promising marker in infertile women with polycystic ovarian disease. Middle East Fertil Soc J 2008; 13: 28-32
    PubMedGoogle Scholar
  • 35 Wasan I, Raya S, Widad A. Serum prostate specific antigen level in women with polycystic ovary syndrome. J Fac Med Baghdad 2016; 58: 136-139
    PubMedGoogle Scholar
  • 36 Ükinç K, Ersoz HO, Erem C, Hacihasanoglu AB. Diagnostic value of prostate-specific antigen (PSA) and free prostate specific antigen (fPSA) in women with ovulatory and anovulatory polycystic ovary syndrome. Endocrine 2009; 35: 123-129
    CrossrefPubMedGoogle Scholar
  • 37 Rudnicka E, Radowicki S, Suchta K. Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome–a new insight. Gynecol Endocrinol 2016; 32: 931-935
    CrossrefPubMedGoogle Scholar
  • 38 Mardanian F, Heidari N. Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome. J Res Med Sci 2011; 16: 999
    PubMedGoogle Scholar
  • 39 Mohajir Hussein AM, Hussein E, Eltom A. Assessment of serum Prostate specific antigen (PSA) level among Sudanese women with polycystic ovarian syndrome In Khartoum state. Sch J Appl. Med Sci 2017; 5: 1288-1296
    PubMedGoogle Scholar
  • 40 Wang G, Xu R, Zhang Z. Increased level of prostate-specific antigen: a diagnostic marker of hyperandrogenism women. Zhonghua nan ke xue: Natl J Androl 2009; 15: 1028-1030
    PubMedGoogle Scholar
  • 41 Galadari I, Al-Mazroei M, Alkaabi J. Prostatic-specific antigen and idiopathic hirsutism in females. Int J Dermatol 2004; 43: 275-277
    CrossrefPubMedGoogle Scholar
  • 42 Bili E, Dampala K, Iakovou I. et al. The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs). Eur J Obstet Gynecol Reprod Biol 2014; 179: 32-35
    CrossrefPubMedGoogle Scholar
  • 43 Melegos DN, Yu H, Ashok M. et al. Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab 1997; 82: 777-780
    CrossrefPubMedGoogle Scholar
  • 44 Noldus J, Chen Z, Stamey TA. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 1997; 158: 1606-1609
    CrossrefPubMedGoogle Scholar
  • 45 Borchert G, Melegos D, Tomlinson G. et al. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer 1997; 76: 1087-1094
    CrossrefPubMedGoogle Scholar
  • 46 Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994; 78: 1536-1539
    PubMedGoogle Scholar
  • 47 Wernert N, Albrech M, Sesterhenn I. et al. The 'female prostate': Location, morphology, immunohistochemical characteristics and significance. Eur Urol 1992; 22: 64-69
    CrossrefPubMedGoogle Scholar
  • 48 Aksoy H, Akçay F, Umudum Z. et al. Changes of PSA concentrations in serum and saliva of healthy women during the menstrual cycle. Ann Clin Lab Sci 2002; 32: 31-36
    PubMedGoogle Scholar
  • 49 Lambert-Messerlian GM, Canick JA, Melegos DN. et al. Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down syndrome. Clin Chem 1998; 44: 205-208
    CrossrefPubMedGoogle Scholar
  • 50 Stemp M, Roberts P, McClements A. et al. Serum concentrations of the biomarkers CA125, CA15-3, PSA and PAPP-A in early pregnancy. J Reprod Biotechnol Fertil 2016; 5: 2058915816672102
    PubMedGoogle Scholar
  • 51 Wald N, Hackshaw A, Diamandis E. et al. Maternal serum prostatespecific antigen and Down syndrome in the first and second trimesters of pregnancy. Prenat Diagnos 1999; 19: 674-676
    PubMedGoogle Scholar
  • 52 Yu H, Diamandis EP. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem 1995; 41: 54-58
    CrossrefPubMedGoogle Scholar
  • 53 Yu H, Diamandis EP. Prostate-specific antigen in milk of lactating women. Clin Chem 1995; 41: 54-58
    CrossrefPubMedGoogle Scholar
  • 54 Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 1997; 24: 275-282
    CrossrefPubMedGoogle Scholar
  • 55 Cleutjens KB, van der Korput HA, van Eekelen CC. et al. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997; 11: 148-161
    CrossrefPubMedGoogle Scholar
  • 56 Shan J-D, Porvari K, Ruokonen M. et al. Steroid-involved transcriptional regulation of human genes encoding prostatic acid phosphatase, prostate-specific antigen, and prostate-specific glandular kallikrein. Endocrinology 1997; 138: 3764-3770
    CrossrefPubMedGoogle Scholar
  • 57 Zarghami N, Grass L, Diamandis E. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cance 1997; 75: 579-588
    PubMedGoogle Scholar
  • 58 Lilja H. Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World J Urol 1993; 11: 188-191
    PubMedGoogle Scholar
  • 59 Levesque M, Hu H, Diamandis EP. et al. Prostate-Specific antigen expression by various tumors. J Clin Lab Anal 1995; 9: 123-128
    CrossrefPubMedGoogle Scholar
  • 60 Yu H, Diamandis EP, Levesque M. et al. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res 1995; 55: 1603-1606
    PubMedGoogle Scholar
  • 61 Burger HG. Androgen production in women. Fertility and Sterility 2002; 77: 3-5
    PubMedGoogle Scholar
  • 62 Escobar-Morreale HF, Serrano-Gotarredona J, Avila S. et al. The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab 1998; 83: 2580-2584
    CrossrefPubMedGoogle Scholar
  • 63 Manetti L, Lupi I, Genovesi M. et al. Serum prostate-specific antigen concentration is increased in acromegalic women. J Endocrinol Invest 2004; 27: 643-647
    CrossrefPubMedGoogle Scholar
  • 64 Diamandis EP, Eklund E, Muytjens C. et al. Effect of age on serum prostate-specific antigen in women. Clin Chem Lab Med 2017; 55: e271-e272
    PubMedGoogle Scholar
  • 65 Giai M, Yu H, Roagna R. et al. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer 1995; 72: 728
    CrossrefPubMedGoogle Scholar
  • 66 Yu H, Diamandis EP. Prostate Cancer: Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J Urol 1995; 153: 1004-1008
    CrossrefPubMedGoogle Scholar
  • 67 Yu H, Diamandis EP, Levesque M. et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 1996; 40: 171-178
    CrossrefPubMedGoogle Scholar
  • 68 Azziz R, Carmina E, Dewailly D. et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245
    CrossrefPubMedGoogle Scholar
  • 69 Johnson T, Kaplan L, Ouyang P. et al. National Institutes of Health evidence-based methodology workshop on polycystic ovary syndrome (PCOS). NIH EbMW Report Bethesda, National Institutes of Health 2012; 1: 1-14
    PubMedGoogle Scholar
  • 70 Bock JL, Klee GG. How Sensitive Is a Prostate-Specific Antigen Measurement?: How Sensitive Does It Need to Be?. Arch Pathol Lab Med 2004; 128: 341-343
    CrossrefPubMedGoogle Scholar
  • 71 McDermed JE, Sanders R, Fait S. et al. Nucleic acid detection immunoassay for prostate-specific antigen based on immuno-PCR methodology. Clin Chem 2012; 58: 732-740
    CrossrefPubMedGoogle Scholar
  • 72 Wilson DH, Hanlon DW, Provuncher GK. et al. Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. Clin Chem 2011; 57: 1712-1721
    CrossrefPubMedGoogle Scholar
  • 73 Zarghami N, Grass L, Sauter ER. et al. Prostate-specific antigen in serum during the menstrual cycle. Clin Chem 1997; 43: 1862-1867
    CrossrefPubMedGoogle Scholar